Tuberculosis Clinical Trial
Official title:
A Natural History Study of Tuberculosis in China; Correlates of a Successful Response to Treatment
Background:
- In spite of well-researched treatments and therapies, 5 to 10 percent of tuberculosis (TB)
patients who have initially successful TB treatments will relapse, usually within a year
after completion of therapy. This percentage is even greater for patients who are infected
with multi-drug resistant and extensively drug resistant types of TB. Because the People s
Republic of China has the second highest number of TB cases in the world, researchers are
interested in studying TB patients in China to evaluate their response to treatment on a
long-term basis.
Objectives:
- To improve TB diagnosis and testing by determining the number and proportion of patients
admitted with suspected TB who actually have TB (definite or probable).
- To assess the prevalence of non-tuberculosis bacteria among patients with presumed TB.
Eligibility:
- Individuals between 18 and 65 years of age who have been admitted to Henan Provincial Chest
Hospital with suspected tuberculosis.
Design:
- Participants will be divided into three groups, based on their diagnosis after
admission. Another group of individuals who do not have TB will be enrolled as controls
for comparison purposes during the study.
- The study will use computed tomography (CT) scans of the chest at initial enrollment, 2
months, and 6 months to evaluate disease response to treatment. Incidents of TB that are
not in the chest area (extrapulmonary TB) will also be studied.
- The study will also monitor the treatments and therapies used against the disease,
changes in patients immune systems, and any changes in the biological samples taken over
the course of treatment.
Despite optimal antimicrobial treatment with directly observed short-course therapy (DOTS),
about 5-10 percent of drug-compliant patients with cured tuberculosis (TB or MTB) relapse,
usually within a year after completion of therapy. This percentage is even greater for
patients that have previously been treated for TB who often are infected with multi-drug
resistant (MDR) and extensively drug resistant (XDR) organisms. The People s Republic of
China has the second highest number of cases of TB in the world, with a rate of 101
cases/100,000 person-years estimated for 2004. Based on the data of the 4th national TB
epidemiological survey in 2000, it is estimated that there were 1.96 million instances of
pulmonary TB. With an established MDR TB prevalence of 10.7 percent, there were an estimated
209,720 cases of pulmonary, bacteriology confirmed MDR TB in China in 2000. About half of all
prevalent cases of TB disease in 2000 were extrapulmonary.
This prospective longitudinal natural history study will monitor 150 subjects with suspected
TB at the Henan Provincial Chest Hospital during their initial response to antituberculous
chemotherapy. The subjects will be divided into 3 groups of TB-infected individuals: Cohort
A) acid-fast bacilli (AFB) smear positive pulmonary disease; Cohort B) smear negative
pulmonary disease; and Cohort C) extra-pulmonary disease (EPTB) in order to reflect the
spectrum of TB manifestations observed at Henan Provincial Chest Hospital. We will also be
enrolling 45 non-TB suspects as controls (Cohort D). The control group will serve as a
comparison group for exploratory immunologic and diagnostic assays that may, in the future,
serve as ways to diagnose TB and/or evaluate response to therapy.
In this exploratory study, we will be looking at the change in total volume of disease as
detected by computerized tomography scans of the chest at baseline, at 2 months, and at 6
months. We will also be looking at scanned regions of extrapulmonary TB. In addition, we will
monitor chemotherapeutic regimen, changes in the host immune response, overall changes in
clinical parameters, initial and acquired drug-resistance of the infecting isolates, and
changes in bacterial and host markers in subject samples during chemotherapy. In each case,
we will look for associations of these parameters with rates of disease resolution correlated
with specific structural features determined by computerized tomography scanning of the sites
of TB disease (with the exception of TB meningitis and cutaneous TB, for which there are no
specific lesions to follow radiographically). These studies will allow us to evaluate the use
of entry criteria in future clinical trials and eventual TB diagnosis confirmation using
these entry categorizations. We will also be able to examine the impact of initial regimen
selection, and subsequent modifications, mycobacterial strain characteristics, extent of
disease, types of lesions and host immunologic response to the overall outcome of
chemotherapy, as well as potentially identify surrogate markers for improving monitoring of
the response to chemotherapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |